Trials / Completed
CompletedNCT00811798
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 25 Years
- Healthy volunteers
- Accepted
Summary
This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before they are 25 years, and were placebo recipients in the primary study (NCT00306241).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cervarix | Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2008-12-19
- Last updated
- 2016-10-20
- Results posted
- 2011-10-13
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT00811798. Inclusion in this directory is not an endorsement.